Develops genetic medicines that silence disease-causing genes and replace them with functional genes, including a therapy for people with OPMD.
10-K for FY2026, filed Sep 14, 2026Benitec Biopharma Inc. (“Benitec” or the “Company” or in the first person, “we” or “our”) is a clinical-stage biotechnology company focused…View ↗
Our proprietary technology platform is designated as DNA-directed RNA interference, or “ddRNAi”, and “silence and replace.” ddRNAi is…View ↗
Our strategy is to discover, develop and commercialize treatments that leverage the capabilities of ddRNAi and the silence and replace…View ↗
Loading...